Estrogen Receptor Signaling in Lung Cancer

Seminars in Oncology

Volumn 36, Issue 6, 2009, Pages 524-531

  Siegfried, Jill M ^a   Hershberger, Pamela A ^a   Stabile, Laura P ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EXEMESTANE; FULVESTRANT; LETROZOLE; PLACEBO; TAMOXIFEN;

ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; DRUG MECHANISM; ESTROGEN RESPONSIVE ELEMENT; FEMALE GENITAL SYSTEM; GENE EXPRESSION REGULATION; GENOME; HORMONE SUBSTITUTION; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MITOCHONDRION; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR BINDING; SEX DIFFERENCE; SIGNAL TRANSDUCTION; WOMEN'S HEALTH;

AROMATASE; CARCINOMA, NON-SMALL-CELL LUNG; ESTRADIOL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 71049145347     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2009.10.004     Document Type: Article

References (69)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Muscat J.E., and Wynder E.L. Lung cancer pathology in smokers, ex-smokers and never smokers. Cancer Lett 88 (1995) 1-5
3. Ryberg D., Hewer A., Phillips D.H., and Haugen A. Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res 54 (1994) 5801-5803
4. Mollerup S., Ryberg D., Hewer A., Phillips D.H., and Haugen A. Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res 59 (1999) 3317-3320
5. Wei Q., Cheng L., Amos C.I., Wang L.E., Guo Z., Hong W.K., et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 92 (2000) 1764-1772
6. Fu J.B., Severson R.K., and Kalemkerian G.P. Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. Chest 127 (2005) 768-777
7. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
8. Wakelee H.A., Chang E.T., Gomez S.L., Keegan T.H., Feskanich D., Clarke C.A., et al. Lung cancer incidence in never smokers. J Clin Oncol 25 (2007) 481-488
9. Albain K.S., Unger J.M., Gotay C.C., Davies A.M., Edelman M., Herbst R.S., et al. Toxicity and survival by sex in patients with advanced non-small cell lung carcinoma on modern Southwest Oncology Group (SWOG) trials. J Clin Oncol 25 (2007) 7549
10. Ganti A.K., Sahmoun A.E., Panwalkar A.W., Tendulkar K.K., and Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 24 (2006) 59-63
11. Chlebowski R.T., Schwartz A.G., Wakelee H., Anderson S.L., Stefanick M.L., Manson J.E., et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): post-hoc analysis of a randomised controlled trial. Lancet (Sep 18, 2009) [Epub ahead of print]
12. Ramnath N., Menezes R.J., Loewen G., Dua P., Eid F., Aikhaddo J., et al. Hormone replacement therapy as a risk factor for non-small cell lung cancer: results of case-control study. Oncology 73 (2007) 305-310
13. Schwartz A.G., Wenzlaff A.S., Prysak G.M., Murphy V., Cote M.L., Brooks S.C., et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J Clin Oncol 25 (2007) 5785-5792
14. Fu X.D., Cui Y.H., Lin G.P., and Wang T.H. Non-genomic effects of 17beta-estradiol in activation of the ERK1/ERK2 pathway induces cell proliferation through upregulation of cyclin D1 expression in bovine artery endothelial cells. Gynecol Endocrinol 23 (2007) 131-137
15. Belcher S.M., Ma X., and Le H.H. Blockade of estrogen receptor signaling inhibits growth and migration of medulloblastoma. Endocrinology 150 (2009) 1112-1121
16. Kato S., Endoh H., Masuhiro Y., Kitamoto T., Uchiyama S., Sasaki H., et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270 (1995) 1491-1494
17. Ishibashi H., Suzuki T., Suzuki S., Niikawa H., Lu L., Miki Y., et al. Progesterone receptor in non-small cell lung cancer-a potent prognostic factor and possible target for endocrine therapy. Cancer Res 65 (2005) 6450-6458
18. Frasor J., Danes J.M., Komm B., Chang K.C.N., Lyttle C.R., and Katzenellenbogen B.S. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144 (2003) 4562-4574
19. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., and Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 93 (1996) 5925-5930
20. Mosselman S., Polman J., and Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 392 (1996) 49-53
21. Delaunay F., Pettersson K., Tujague M., and Gustafsson J.A. Functional differences between the amino-terminal domains of estrogen receptors alpha and beta. Mol Pharmacol 58 (2000) 584-590
22. Lau K.M., LaSpina M., Long J., and Ho S.M. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res 60 (2000) 3175-3182
23. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 (1997) 753-758
24. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 (1998) 927-937
25. Stabile L.P., Davis A.L., Gubish C.T., Hopkins T.M., Luketich J.D., Christie N., et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 62 (2002) 2141-2150
26. Hershberger P.A., Stabile L.P., Kanterewicz B., Rothstein M.E., Gubish C.T., Land S., et al. Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells. J Steroid Biochem Mol Biol 116 (2009) 102-109
27. Ciana P., DiLuccio G., Belcredito S., Pollio G., Vegeto E., Tatangelo L., et al. Engineering of a mouse for the in vivo profiling of estrogen receptor activity. Mol Endocrinol 15 (2001) 1104-1113
28. Lemmen J.G., Arends R.J., van Boxtel A.L., van der Saag P.T., and van der Burg B. Tissue- and time-dependent estrogen receptor activation in estrogen reporter mice. J Mol Endocrinol 32 (2004) 689-701
29. Patrone C., Cassel T.N., Pettersson K., Piao Y.-S., Cheng G., Ciana P., et al. Regulation of postnatal lung development and homeostasis by estrogen receptor β. Mol Cell Biol 23 (2003) 8542-8552
30. Morani A., Barros R.P., Imamov O., Hultenby K., Arner A., Warner M., et al. Lung dysfunction causes systemic hypoxia in estrogen receptor beta knockout (ERbeta-/-) mice. Proc Natl Acad Sci U S A 103 (2006) 7165-7169
31. Kawai H., Ishii A., Washiya K., Konno T., Kon H., Yamaya C., et al. Combined overexpression of EGFR and estrogen receptor alpha correlates with a poor outcome in lung cancer. Anticancer Res 25 (2005) 4693-4698
32. Wu C.T., Chang Y.L., Shih J.Y., and Lee Y.C. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg 130 (2005) 979-986
33. Schwartz A.G., Prysak G.M., Murphy V., Lonardo F., Pass H., Schwartz J., et al. Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res 11 (2005) 7280-7287
34. Skov B.G., Fischer B.M., and Pappot H. Oestrogen receptor b over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer 59 (2008) 88-94
35. Osborne C.K., Yochmowitz M.G., Knight III W.A., and McGuire W.L. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46 (1980) 2884-2888
36. Thorpe S.M., Rose C., Rasmussen B.B., Mouridsen H.T., Bayer T., and Keiding N. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res 47 (1987) 6126-6133
37. Maggiolini M., and Picard D. The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J Endocrinol (Sep 18, 2009) [Epub ahead of print]
38. Pietras R.J., Marquez D.C., Chen H.W., Tsai E., Weinberg O., and Fishbein M. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 70 (2005) 372-381
39. Stabile L.P., Lyker J.S., Gubish C.T., Zhang W., Grandis J.R., and Siegfried J.M. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced anti-proliferative effects. Cancer Res 65 (2005) 1459-1470
40. Zhang G., Liu X., Farkas A.M., Parwani A.V., Lathrop K.L., Lenzner D., et al. Estrogen receptor beta functions through nongenomic mechanisms in lung cancer cells. Mol Endocrinol 23 (2009) 146-156
41. Marquez-Garban D.C., Chen H.W., Fishbein M.C., Goodglick L., and Pietras R.J. Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids 72 (2007) 135-143
42. Traynor A.M., Schiller J.H., Stabile L.P., Kolesar J.M., Belani C.P., Hoang T., et al. Combination treatment with gefitinib and fulvestrant for post-menopausal women with advanced non-small cell lung cancer. Lung Cancer 64 (2009) 51-59
43. Garon E.B., Sadeghi S., Kabbinavar F.F., Reckamp K.L., Marquez-Garban D.C., Stabile L.P., et al. Interim safety analysis of a phase II study of erlotinib (E) alone or combined with fulvestrant (F) in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting abstracts) 26 (2008) 19091
44. Pedram A., Razandi M., Wallace D.C., and Levin E.R. Functional estrogen receptors in the mitochondria of breast cancer cells. Mol Biol Cell 17 (2006) 2125-2137
45. Mattingly K.A., Ivanova M.M., Riggs K.A., Wickramasinghe N.S., Barch M.J., and Klinge C.M. Estradiol stimulates transcription of nuclear respiratory factor-1 and increases mitochondrial biogenesis. Mol Endocrinol 22 (2008) 609-622
46. Yang S.H., Sarkar S.N., Liu R., Perez E.J., Wang X., Wen Y., et al. Estrogen receptor beta as a mitochondrial vulnerability factor. J Biol Chem 284 (2009) 9540-9548
47. Chen J.Q., Eshete M., Alworth W.L., and Yager J.D. Binding of MCF-7 cell mitochondrial proteins and recombinant human estrogen receptors alpha and beta to human mitochondrial DNA estrogen response elements. J Cell Biochem 93 (2004) 358-373
48. Klinge C.M. Estrogenic control of mitochondrial function and biogenesis. J Cell Biochem 105 (2008) 1342-1351
49. Simpkins J.W., Yang S.H., Sarkar S.N., and Pearce V. Estrogen actions on mitochondria--physiological and pathological implications. Mol Cell Endocrinol 290 (2008) 51-59
50. Virbasius C.A., Virbasius J.V., and Scarpulla R.C. NRF-1, an activator involved in nuclear-mitochondrial interactions, utilizes a new DNA-binding domain conserved in a family of developmental regulators. Genes Dev 7 (1993) 2431-2445
51. Yang S.H., Liu R., Perez E.J., Wen Y., Stevens Jr. S.M., Valencia T., et al. Mitochondrial localization of estrogen receptor beta. Proc Natl Acad Sci U S A 101 (2004) 4130-4135
52. Chen J.Q., Delannoy M., Cooke C., and Yager J.D. Mitochondrial localization of ERalpha and ERbeta in human MCF7 cells. Am J Physiol Endocrinol Metab 286 (2004) E1011-E1022
53. Milanesi L., Vasconsuelo A., de Boland A.R., and Boland R. Expression and subcellular distribution of native estrogen receptor beta in murine C2C12 cells and skeletal muscle tissue. Steroids 74 (2009) 489-497
54. Cammarata P.R., Chu S., Moor A., Wang Z., Yang S.H., and Simpkins J.W. Subcellular distribution of native estrogen receptor alpha and beta subtypes in cultured human lens epithelial cells. Exp Eye Res 78 (2004) 861-871
55. Hammoud Z., Tan B., Badve S., and Bigsby R.M. Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma. Endocr Relat Cancer 15 (2008) 475-483
56. Hershberger P.A., Vasquez A.C., Kanterewicz B., Land S., Siegfried J.M., and Nichols M. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res 65 (2005) 1598-1605
57. Jarzynka M.J., Guo P., Bar-Joseph I., Hu B., and Cheng S.Y. Estradiol and nicotine exposure enhances A549 bronchioloalveolar carcinoma xenograft growth in mice through the stimulation of angiogenesis. Int J Oncol 28 (2006) 337-344
58. Weinberg O.K., Marquez-Garban D.C., Fishbein M.C., Goodglick L., Garban H.J., Dubinett S.M., et al. Aromatase inhibitors in human lung cancer therapy. Cancer Res 65 (2005) 11287-11291
59. Martel C., Melner M.H., Gagné D., Simard J., and Labrie F. Widespread tissue distribution of steroid sulfatase, 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD), 17 beta-HSD 5 alpha-reductase and aromatase activities in the rhesus monkey. Mol Cell Endocrinol 104 (1994) 103-111
60. Price T., Aitken J., and Simpson E.R. Relative expression of aromatase cytochrome P450 in human fetal tissues as determined by competitive polymerase chain reaction amplification. J Clin Endocrinol Metab 74 (1992) 879-883
61. Marquez-Garban D.C., Chen H.W., Goodglick L., Fishbein M.C., and Pietras R.J. Targeting aromatase and estrogen signaling in human non-small cell lung cancer. Ann N Y Acad Sci 1155 (2009) 194-205
62. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 35011 (2004) 1081-1092
63. Mah V., Seligson D.B., Li A., Marquez D.C., Wistuba I.I., Elshimali Y., et al. Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res 67 (2007) 10484-10490
64. Buzdar A.U., Coombes R.C., Goss P.E., and Winer E.P. Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer 112 (2008) 700-709
65. Eisen A., Trudeau M., Shelley W., Messersmith H., and Pritchard K.I. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. Cancer Treat Rev 34 (2008) 157-174
66. Wang Y., and Brown M. Molecular determinants for the tissue specificity of SERMs. Science 295 (2002) 2465-2468
67. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90 (1998) 1371-1388
68. Niikawa H., Suzuki T., Miki Y., Suzuki S., Nagasaki S., Akahira J., et al. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res 14 (2008) 4417-4426
69. Wang P.-H., Wang H.-C., and Tsai C.-C. Estrogen replacement in female lung cancer during gefitinib therapy. Jpn J Clin Oncol 10 (2009) [Epub ahead of print]